A Review: Stereochemical consideration and eudismic ratio in chiral drug development

Over the past fifteen to twenty years, the stereochemistry is gaining prime importance in pharmaceutical practice. As a result of advancement in chemical technologies associated with the synthesis, separation, identification and analysis of single enantiomer present in racemic compound, several chiral drugs are presented as single enantiomer for approval to regulatory authorities. Rather to introduce a racemic compound, a single enantiomer always have better selectivity on receptor resulting in superior therapeutics action with less metabolic load and less side effects. The enzymes or amino acids or binding sites have long been recognized to be stereoselective which is considered in chiral drug development. Each enantiomer interacts differently with the receptor, elicits the response differently and potency of enantiomer depends on the eudismic ratio or eudismic index or stereospecific index of the compound. Therefore Eudismic ratio is also an important tool in chiral drug designing. The issues related to eudismic ratio are presented in this review article and it facilitates us for single enantiomer development.